State Street’s Soleno Therapeutics SLNO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-2,680,802
Closed -$89.8M 4264
2026
Q1
$89.8M Buy
2,680,802
+31,176
+1% +$1.22M ﹤0.01% 1431
2025
Q4
$123M Buy
2,649,626
+476,590
+22% +$26.1M ﹤0.01% 1241
2025
Q3
$147M Buy
2,173,036
+768,053
+55% +$56.9M 0.01% 1128
2025
Q2
$118M Buy
1,404,983
+235,784
+20% +$17.6M ﹤0.01% 1215
2025
Q1
$83.5M Sell
1,169,199
-177,820
-13% -$8.66M ﹤0.01% 1360
2024
Q4
$60.5M Buy
1,347,019
+204,850
+18% +$10.6M ﹤0.01% 1631
2024
Q3
$57.7M Buy
1,142,169
+142,033
+14% +$6.8M ﹤0.01% 1629
2024
Q2
$40.8M Buy
1,000,136
+29,566
+3% +$1.25M ﹤0.01% 1775
2024
Q1
$41.5M Buy
970,570
+469,168
+94% +$21.2M ﹤0.01% 1816
2023
Q4
$20.2M Buy
501,402
+485,954
+3,146% +$13.8M ﹤0.01% 2206
2023
Q3
$456K Hold
15,448
﹤0.01% 3688
2023
Q2
$66.3K Hold
15,448
﹤0.01% 4337
2023
Q1
$33.1K Hold
15,448
﹤0.01% 4607
2022
Q4
$30.6K Hold
15,448
﹤0.01% 4665
2022
Q3
$26K Sell
15,448
-1
-0% -$2 ﹤0.01% 4788
2022
Q2
$43K Hold
15,449
﹤0.01% 4749
2022
Q1
$52K Buy
15,449
+776
+5% +$4.02K ﹤0.01% 4784
2021
Q4
$90K Hold
14,673
﹤0.01% 4600
2021
Q3
$203K Hold
14,673
﹤0.01% 4356
2021
Q2
$251K Sell
14,673
-41,753
-74% -$705K ﹤0.01% 4129
2021
Q1
$1.07M Buy
56,426
+8,334
+17% +$269K ﹤0.01% 3612
2020
Q4
$1.39M Buy
48,092
+22,403
+87% +$647K ﹤0.01% 3490
2020
Q3
$967K Buy
25,689
+5,765
+29% +$168K ﹤0.01% 3448
2020
Q2
$663K Buy
+19,924
New +$863K ﹤0.01% 3502

State Street's SLNO Position: Q2 2026 in Review

State Street sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 2,680,802 shares — an estimated $89.8M sold.

State Street first reported a position in SLNO in Q2 2020 and held it in 24 quarters. The position peaked at $147M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • State Street reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • State Street sold 2,680,802 Soleno Therapeutics shares in Q2 2026, an estimated $89.8M.
  • State Street first reported a position in Soleno Therapeutics in Q2 2020 and held it in 24 quarters.
  • State Street's Soleno Therapeutics position peaked at $147M in Q3 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.